Press release
May 8, 2026
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
Boundless Bio, Inc. (BOLD)
Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating